NuuVim vs Embody
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
Best for: knowing which pharmacy fills the vial — it names RedRock Pharmacy
Visit Embody →Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, both start around $79/mo, and Embody finishes ahead, 9.3 to 7.7. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
NuuVim
Embody
Checkout: '$79/mo flat forever' (strikethrough $299); bundles $76/$73/$69 per month on 3/6/12-mo. CAVEAT: T&C list price is $199/mo — the $79 depends on the auto-applied SUMMER promo marketed as permanently locked; Trustpilot complaints allege the lock was not always honored.
Checkout tile 'Flat rate at $119/month (strikethrough $349)'; homepage 'starting at $129/month'; bundles $126/$123/$119 per month.
New oral semaglutide $229/mo.
Oral tirzepatide $329/mo; gum bundles to $299/mo at 12-month.
What’s included
NuuVim
Covered by the monthly price
Medication
In the price
Clinician visits
Not stated
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Embody
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
NuuVim
7.7/10
Embody
9.3/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | NuuVim | Embody |
|---|---|---|
| Starting Price | $79/mo | $79/mo |
| Features | ✓7 features | 6 features |
| States Available | Not disclosed | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | 4 warnings | ✓None |
About NuuVim
NuuVim advertises compounded semaglutide from $79/month and tirzepatide from $133/month for new users, flat across all doses with no extra fees. The Texas-based program sells both injectable and oral forms, an uncommon oral option here, plus limited brand-name Ozempic and Zepbound. It is LegitScript-certified and HIPAA-compliant, serves all 50 states plus DC, and names two pharmacy partners.
Read our full NuuVim review →About Embody
Embody sells compounded semaglutide and tirzepatide by injection, plus a compounded oral tirzepatide gum that is unique in the category. Flat-rate pricing is aggressive, coverage runs to all 50 states, and clinician messaging is available 24/7 under a board-certified internal medicine CMO.
Read our full Embody review →Pros & Cons
NuuVim
What we like
- Semaglutide at $79 a month, 58% below the $189 median for the same drug and form across this register
- Tirzepatide at $133 a month, 50% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication and shipping
- Both oral and injectable options are on record, so the format is a choice rather than a condition
Watch-outs
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 4 FDA warning letters matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Embody
What we like
- Semaglutide at $79 a month, 58% below the $189 median for the same drug and form across this register
- Tirzepatide at $129 a month, 52% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- Names 4 dispensing pharmacies, which most sellers in this register do not do
- No FDA warning letter matched this operator when we searched our enforcement register
- Both oral and injectable options are on record, so the format is a choice rather than a condition
Watch-outs
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Embody takes it, 9.3 against 7.7, and it is especially strong on knowing which pharmacy fills the vial — it names RedRock Pharmacy. NuuVim is no weak second and may fit you better on semaglutide at $79/month, 58% under the register median.
Choose NuuVim if…
You want semaglutide at $79/month, 58% under the register median and an opening price near $79 a month.
Choose Embody if…
You want knowing which pharmacy fills the vial — it names RedRock Pharmacy and an opening price near $79 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Telos Rx
Starting below a standard dose, with microdose tiers
From $49/mo
Get started →MyDrHank
An oral route if you will not self-inject
From $25/mo
Get started →SkinnyRx
Starting below a standard dose, with microdose tiers
From $149.25/mo
Get started →NuuVim vs Embody: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring NuuVim and Embody head-to-heads in the same category.
- NuuVim vs Trimi Health
- NuuVim vs He & She MD
- NuuVim vs Lean Meds
- Embody vs NextMeds
- Embody vs bmiMD
- Embody vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.